PRPH ProPhase Labs (PRPH) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000868278
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
ProPhase Labs insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for ProPhase Labs, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.4% of the 30,991 shares held after it.
- No other insider bought within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Barr Jason Michael bought about $4.9K of PRPH on Mar 10, 2022, the largest insider purchase at the company on our record.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.3% of the 30,962 shares held after it.
- No other insider bought within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Barr Jason Michael bought about $4.7K of PRPH on Mar 10, 2022, the largest insider purchase at the company on our record.2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-35.8% year over year
below 75% of Pharma & Biotech
Margin
-339.3% net margin
below 74% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.5% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 79% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PRPH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-99.7%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PRPH: institutional holders (13F)
13F holdings, latest reported quarter
$1
Congress trades in PRPH
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PRPH planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Ted Karkus
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$2.1M
$497.2K
$1.8M
-92%
n/a
2023
$3.4M
$1.9M
$370.7K
-53%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
PRPH financials
Revenue growth
-35.8%
XBRL, annual
Net margin
-339.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PRPH
| FY Dec 2025 | $4.3M |
| FY Dec 2024 | $6.8M |
| FY Dec 2023 | $44.4M |
| FY Dec 2022 | $122.7M |
| FY Dec 2021 | $79.1M |
| Jun 2026 | $1.0M |
| Mar 2026 | $1.2M |
| Dec 2025 | $784.0K |
| Sep 2025 | $883.0K |
| Jun 2025 | $1.2M |
| Mar 2025 | $1.4M |
| Dec 2024 | -$2.5M |
| Sep 2024 | $3.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-583.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PRPH
| FY Dec 2025 | -339.3% |
| FY Dec 2024 | -788.2% |
| FY Dec 2023 | -37.8% |
| FY Dec 2022 | +15.1% |
| FY Dec 2021 | +7.9% |
| Jun 2026 | -301.8% |
| Mar 2026 | -442.7% |
| Dec 2025 | -943.6% |
| Sep 2025 | -774.5% |
| Jun 2025 | -358.6% |
| Mar 2025 | +277.1% |
| Dec 2024 | n/a |
| Sep 2024 | -209.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$5.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PRPH
| FY Dec 2025 | -$8.3M |
| FY Dec 2024 | -$18.4M |
| FY Dec 2023 | -$14.0M |
| FY Dec 2022 | $24.6M |
| FY Dec 2021 | -$17.9M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$1.2M |
| Sep 2025 | -$3.5M |
| Jun 2025 | -$247.0K |
| Mar 2025 | -$3.4M |
| Dec 2024 | -$3.6M |
| Sep 2024 | -$4.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity PRPH
| FY Dec 2025 | 1.53x |
| FY Dec 2024 | 0.83x |
| FY Dec 2023 | 0.06x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 1.53x |
| Sep 2025 | 0.78x |
| Jun 2025 | 0.47x |
| Mar 2025 | 0.36x |
| Dec 2024 | 0.83x |
| Sep 2024 | 0.15x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.03x
TTM operating cash flow over long-term 2023-12-31 (30 months older than the period end) plus current 2025-03-31 (15 months older than the period end)
Cash flow to debt PRPH
| FY Dec 2025 | -1.55x |
| FY Dec 2024 | -2.86x |
| FY Dec 2023 | -4.07x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -1.03x |
| Mar 2026 | -1.06x |
| Dec 2025 | -1.55x |
| Sep 2025 | -1.98x |
| Jun 2025 | -2.08x |
| Mar 2025 | -2.94x |
| Dec 2024 | -2.86x |
| Sep 2024 | -2.64x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-539.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PRPH
| FY Dec 2025 | -271.5% |
| FY Dec 2024 | -188.1% |
| FY Dec 2023 | -29.7% |
| FY Dec 2022 | +30.2% |
| FY Dec 2021 | +18.1% |
| Jun 2026 | -539.7% |
| Mar 2026 | -325.3% |
| Dec 2025 | -271.5% |
| Sep 2025 | -185.4% |
| Jun 2025 | -149.3% |
| Mar 2025 | -143.8% |
| Dec 2024 | -188.1% |
| Sep 2024 | -58.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-45.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PRPH
| FY Dec 2025 | -24.0% |
| FY Dec 2024 | -68.8% |
| FY Dec 2023 | -18.7% |
| FY Dec 2022 | +20.9% |
| FY Dec 2021 | +10.4% |
| Jun 2026 | -45.2% |
| Mar 2026 | -44.0% |
| Dec 2025 | -24.0% |
| Sep 2025 | -53.0% |
| Jun 2025 | -61.1% |
| Mar 2025 | -61.6% |
| Dec 2024 | -68.8% |
| Sep 2024 | -30.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital PRPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +36.3% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-197.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PRPH
| FY Dec 2025 | -95.3% |
| FY Dec 2024 | -75.6% |
| FY Dec 2023 | -29.8% |
| FY Dec 2022 | +32.5% |
| FY Dec 2021 | +19.8% |
| Jun 2026 | -197.8% |
| Mar 2026 | -116.5% |
| Dec 2025 | -95.3% |
| Sep 2025 | -80.5% |
| Jun 2025 | -76.3% |
| Mar 2025 | -75.2% |
| Dec 2024 | -75.6% |
| Sep 2024 | -46.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PRPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 90.85x |
| FY Dec 2021 | 179.25x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.5M
market value at close 2026-10-26 on 2026-08-17 shares, plus long-term 2023-12-31 (30 months older than the period end) plus current 2025-03-31 (15 months older than the period end), minus cash 2026-06-30
Enterprise value PRPH
| FY Dec 2025 | $26.1M |
| FY Dec 2024 | $186.9M |
| FY Dec 2023 | $817.0M |
| FY Dec 2022 | $1.6B |
| FY Dec 2021 | n/a |
| Jun 2026 | $6.6M |
| Mar 2026 | $9.5M |
| Dec 2025 | $26.1M |
| Sep 2025 | $196.1M |
| Jun 2025 | $167.2M |
| Mar 2025 | $172.8M |
| Dec 2024 | $186.9M |
| Sep 2024 | $466.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3,554%
TTM free cash flow over market value at close 2026-10-26
FCF yield PRPH
| FY Dec 2025 | -40.2% |
| FY Dec 2024 | -10.2% |
| FY Dec 2023 | -1.7% |
| FY Dec 2022 | +1.6% |
| FY Dec 2021 | -1.6% |
| Jun 2026 | -439.3% |
| Mar 2026 | -137.4% |
| Dec 2025 | -40.2% |
| Sep 2025 | -5.6% |
| Jun 2025 | -6.9% |
| Mar 2025 | -9.4% |
| Dec 2024 | -10.2% |
| Sep 2024 | -3.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PRPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.55x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $4.3M | $6.8M | $44.4M | $122.6M |
| Gross profit | $1.4M | -$150.0K | $15.6M | $70.7M |
| Operating income | -$18.0M | -$38.6M | -$21.2M | $23.6M |
| Net income | -$14.7M | -$53.4M | -$16.8M | $18.5M |
| EPS (diluted) | -1.74 | -26.68 | -0.98 | 1.02 |
| Operating cash flow | -$8.3M | -$17.5M | -$11.9M | $28.6M |
| Cash | $90.0K | $678.0K | $1.6M | $9.1M |
| Long-term debt | n/a | n/a | $2.9M | $0 |
| Buybacks | n/a | $0 | $588.0K | $2.2M |
| Dividends paid | n/a | n/a | $0 | $9.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
PRPH Stock Sonar score 4/7 axes
Find similar shapesComparePRPH ranks highest on risk and compliance (86th percentile) and financial health (51st), and lowest on profitability (22nd), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
